Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.
Core Innovation
The disclosure describes the preparation and characterization of selinexor crystalline Forms A, B, C, and D using X-ray powder diffraction, differential scanning calorimetry, and thermogravimetric analysis. Form A is characterized by X-ray powder diffraction peaks at 4.4, 19.9, 21.3, and 22.0 2Θ, a melting endotherm near 177–179C, thermodynamic stability as an anhydrous form, and compositions having a unimodal particle-size distribution. Form D is described as a high-yield, high-purity intermediate convertible to Form A.
Independent claims cover methods of treating endometrial cancer or a myeloproliferative disorder by administering an effective amount of the crystalline form of the compound represented by Structural Formula I. The crystalline form is characterized by at least three specified X-ray powder diffraction peaks. Because the background section is not included in the supplied content, the problem being solved is not explicitly described in patent.
Claims Coverage
The claims identify two inventive features across two independent claims: claim 1 for treating endometrial cancer and claim 8 for treating a myeloproliferative disorder.
Treatment of endometrial cancer with the crystalline form
Independent claim 1 covers a method for treating endometrial cancer by administering to a subject in need thereof an effective amount of a crystalline form of the compound represented by Structural Formula I, characterized by at least three X-ray powder diffraction peaks at 2Θ angles selected from 4.4, 19.9, 21.3, and 22.0.
Treatment of a myeloproliferative disorder with the crystalline form
Independent claim 8 covers a method for treating a myeloproliferative disorder by administering to a subject in need thereof an effective amount of a crystalline form of the compound represented by Structural Formula I, characterized by at least three X-ray powder diffraction peaks at 2Θ angles selected from 4.4, 19.9, 21.3, and 22.0.
The independent claims cover administration of the crystalline form for treating endometrial cancer and myeloproliferative disorders, with dependent claims further defining the form by additional X-ray powder diffraction peaks, a differential scanning calorimetry thermogram with an endothermic peak at 179C, or a pattern substantially in accordance with FIG. 1A.
Stated Advantages
The T3P-mediated coupling process is reported to reduce isomerization and side-product formation and to improve purity and yield.
The disclosed process is reported to provide an approximately 80% overall yield at multi-kilogram scale.
Form D is described as a high-yield, high-purity intermediate that can be converted to Form A.
Form A is described as thermodynamically stable.
Documented Applications
Treatment of endometrial cancer by administering an effective amount of the specified crystalline form of the compound represented by Structural Formula I.
Treatment of a myeloproliferative disorder by administering an effective amount of the specified crystalline form of the compound represented by Structural Formula I.
Treatment of CRM1-associated disorders, including cancer, using selinexor.
Interested in licensing this patent?